Public awareness and tighter prescribing restrictions linked to decline in pregabalin misuse
Rates of pregabalin use and related overdose in Australia have levelled off and begun to decline since 2018, a pattern that sets the country apart from many other developed nations where misuse of the drug has continued to climb, according to a study published by The BMJ. The findings suggest that a combination of high-profile media coverage of the harms associated with the medicine, tighter restrictions on prescribing and supply, and the introduction of new boxed warnings played a role in curbing what had been a worrying upward trend. Pregabalin, widely prescribed for nerve pain, epilepsy and anxiety, had been increasingly linked to dependence, sedation and fatal overdose, particularly when used alongside opioids. The Australian experience is being viewed as a potential template for other countries grappling with similar problems.
Pregabalin was originally developed as an anticonvulsant and has become one of the most commonly prescribed medicines in several parts of the world, including for conditions beyond its approved uses. Its sedative effects and potential for dependence have made it a drug of misuse, and international data have shown rising rates of pregabalin-related deaths and hospital presentations in countries such as the United Kingdom and parts of Europe and North America. Australia had itself recorded steep growth in prescribing and in overdose deaths involving the drug during the 2010s, prompting concern among clinicians, regulators and public health experts. The new study examines how the Australian trajectory diverged from that of comparable countries after peaking around 2018.
The BMJ study, which analysed national patterns of use and harm, reports that the levelling off and subsequent decline coincided with a series of policy and public-awareness measures rather than with any single intervention. These included regulatory changes that made pregabalin a controlled or restricted substance in some settings, limits on repeat prescriptions and supply, and boxed warnings highlighting risks such as respiratory depression and misuse. Sustained media reporting on overdose deaths and dependence helped raise awareness among both prescribers and the public. Researchers cautioned that the relationship is associative and that multiple factors, including changes in clinical practice and broader drug-use trends, may have contributed to the shift.
Clinicians and public health researchers have greeted the findings as encouraging evidence that regulatory and awareness measures can influence the trajectory of prescription medicine misuse. Experts quoted in broader coverage of the study have stressed that pregabalin remains a valuable medicine for many patients and that restrictions must be balanced against the risk of denying treatment to those who genuinely need it. Concerns have also been raised that tighter controls can push some users towards illicit supplies or other substances, a pattern seen with other controlled medicines. The study's authors have called for continued monitoring to ensure the decline is sustained and to detect any unintended consequences.
The Australian findings arrive amid growing global scrutiny of prescription medicine misuse, which public health bodies have identified as a significant and often under-recognised contributor to drug-related harm. Unlike illicit drugs, prescription medicines such as pregabalin, benzodiazepines and opioid analgesics enter communities through legitimate clinical channels, making prescribing practices a central lever for harm reduction. Many countries are now weighing tighter scheduling, real-time prescription monitoring and prescriber education. The Australian experience suggests that a combination of regulatory action and public messaging, rather than any single measure, may be most effective in changing prescribing and use patterns.
Historically, similar patterns have been observed with other medicines whose risks became apparent only after widespread use. Opioid prescribing in the United States and benzodiazepine use in several countries followed comparable arcs of rapid uptake, emerging evidence of harm, and eventual policy correction. In each case, the response lagged behind the accumulation of evidence, and the challenge of reversing entrenched prescribing habits proved considerable. The pregabalin story in Australia is notable because the turnaround appears to have come relatively swiftly after the harms were publicised, offering a case study in how quickly a health system can respond when media, regulators and clinicians converge on a shared concern.
Looking ahead, researchers and regulators are expected to continue tracking pregabalin prescribing and overdose data to confirm that the decline persists and to understand which interventions contributed most. The findings are likely to inform debates in other countries considering tighter controls on the drug, as well as broader discussions about how to balance access to effective medicines with protection against misuse. Public health experts will also be watching for signs of substitution, in which users shift to other substances as pregabalin becomes harder to obtain. For now, the Australian data offer a cautiously optimistic signal that coordinated awareness and prescribing restrictions can alter the course of a growing pharmaceutical safety problem.
